A PET study of dopamine function in healthy subjects with hallucinations

Completed

• Conditions: hallucinations; psychosis; 10039628

• Registration Number: NL-OMON33598
• Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 20

Inclusion Criteria

Physically healthy subjects, evaluated by medical history, physical examination and screening laboratory tests
Experiences hallucinations with a frequency of at least once a week.
Total SPQ score lower than 25
No diagnosis on axis I or II based on DSM -IV criteria, confirmed by the CASH and the SCID II interview.
Age between 18-60

Exclusion Criteria

Use of psychotropic medication within four weeks before the scanning
Drug or alcohol-abuse over a period of three weeks prior to the experiment. More then 15 cigarettes and more then 6 cups of caffeine containing coffee, cola or tea.
A history of neurological illness or other medical problems potentially having central nervous system sequellae.
Pregnancy, breast feeding and use of inadequate anti-conception.
Use of other medication potentially influencing cerebral blood flow.
Claustrophobia
Exposure to radioactivity leading to yearly cumulative dose of 10 mSv or more
Metal objects in or around the body (braces, pacemaker, metal fragments);
Exposure to radioactivity leading to a yearly cumulative dose of 10 mSv or more.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>18F-Dopa influx rate constants (Ki) in subjects* striatal brain regions </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>18F-Dopa influx rate constants (Ki) in other brain regions </p><br>